Litcius/Paper detail

Chemotherapy for Muscle-invasive Bladder Cancer: Impact of Cisplatin Delivery on Renal Function and Local Control Rate in the Randomized Phase III VESPER (GETUG-AFU V05) Trial

Stéphane Culine, Valentin Harter, Gwénaëlle Gravis, Aude Fléchon, Christine Chevreau, Hakim Mahammedi, Brigitte Laguerre, Aline Guillot, Florence Joly, Sophie Abadie‐Lacourtoisie, Lionnel Geoffrois, Frédéric FIORE, Guilhem Roubaud, Philippe Barthélémy, Éric Voog, Sheik Emambux, Camille Serrate, Carolina Saldana, Thierry Nguyen-Tan-Hon, Yohann Loriot, Jean‐Christophe Eymard, Olivier Huillard, Frédéric Rolland, Nadine Houédé, Jean‐Philippe Spano, Mounira El Demery, S. Vieillot, Tifenn L’Haridon, Werner Hilgers, Yves Allory, Christian Pfister

2021Clinical Genitourinary Cancer14 citationsDOIOpen Access PDF

Topics & Concepts

MedicineBladder cancerCisplatinUrologyRandomized controlled trialUrothelial cancerOncologyInternal medicineRenal functionChemotherapyCancerBladder and Urothelial Cancer TreatmentsChemotherapy-induced organ toxicity mitigationUrinary Bladder and Prostate Research